SOLVO Biotechnology among the region’s fastest growing

November 2007: The Deloitte Technology Fast 50 Central European annual award honours the fastest growing Central European technology companies, based on percentage revenue growth over a five-year period.

The 2007 winners show exceptional performance. The average five-year revenue growth for all companies was 910 percent A total of eleven Hungarian companies were included on the Technology Fast 50 list. SOLVO Biotechnology took 17th place with a revenue increase of 694 percent.

This was not the first acknowledgement of SOLVO’s performance. In 2004 SOLVO ranked third among 'Rising Stars' in Deloitte & Touche's Technology Fast 50.

This annual competition is a Deloitte initiative at a regional and global level, which aims to draw attention to fast-growing companies and bring to light companies who are just establishing themselves. Winners of the Technology Fast 50 are eligible for the Deloitte Technology Fast 500 EMEA, which ranks the fastest growing technology companies in Europe, the Middle East and Africa.

The Fast 50 program offers participants an exclusive opportunity to:
• Win national exposure
• Enhance your company's credibility
• Network with industry leaders and peers
• Heighten employee morale

Solvo Biotechnology is an early-stage biotech company active in the ADME-Tox field related to ABC-transporters, uptake transporters and also drug resistance. It also holds a number of patents related to drug targets and modulators, gene therapy applications as well as functional aspects of pharmacogenetics/pharmacogenomics.

With close to 50 ABC transporter and uptake transporter assays in its portfolio, SOLVO is the market leader in the field in vitro transporter assays. The various transporter assay results - together with physicochemical data and/or monolayer test results - provide an ADME prediction at relatively low cost before the compounds would enter expensive animal tests. The company also has a multidrug resistance related cancer diagnostics research product on the market. SOLVO's scientific and business excellence stems from its dynamic, dedicated and professional personnel. This enables SOLVO to move towards the discovery and development of other cancer related products. The company's partners include the 10 biggest pharmaceutical and 5 largest biotechnology companies of the world.
 

Contact:

Orsolya Hamar, MBA
Marketing Manager, Business Development
SOLVO Biotechnology
Central Hungarian Innovations Center
Gyár u. 2, Budaörs
H-2040 Hungary
Tel: +36-23-503-940
Fax: +36-23-503-941
www.solvo.com